Adherex to collaborate with AstraZeneca

Guest Contributor
October 24, 2001

Adherex Technologies Inc, Ottawa, has entered a collaboration and option agreement with AstraZeneca plc to further develop the company’s cancer compounds including its lead compound, Exherin, as they move toward human trials. The collaboration begins with a preliminary six-month period during which AstraZeneca scientists will work with Adherex compounds. The collaboration may be extended but neither the terms nor the financial details of the pact are being disclosed….

Other News

Events For Leaders in
Science, Tech, Innovation, and Policy

Discuss and learn from those in the know at our virtual and in-person events.

See Upcoming Events

You have 1 free article remaining.
Don't miss out - start your free trial today.

Start your FREE trial    Already a member? Log in


By using this website, you agree to our use of cookies. We use cookies to provide you with a great experience and to help our website run effectively in accordance with our Privacy Policy and Terms of Service.